---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-24-000225"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T03:28:49.692069+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# KORU Medical Q1 revenue up 11% to $8.2M; gross margin expands 620bps to 62.3%

## Summary
- Net revenues of $8.2M, +10.9% YoY; Core business grew 13.6%, driven by 63% International increase.
- Gross margin 62.3% vs 56.1% YoY, aided by outsourced manufacturing and US site consolidation.
- Net loss narrowed to $1.9M ($0.04/share) from $2.4M; Adj EBITDA loss improved to $0.9M.
- Reaffirmed FY2024 revenue guidance of $31.2-32.2M (10-13% growth); gross margin 59-61% expected.
- Added a novel oncology therapy collaboration, bringing total to 16, with 3 YTD.

## SEC filing metadata
- accession: 0001161697-24-000225
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169724000225/0001161697-24-000225-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169724000225/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-24-000225
- JSON: https://secwatch.observer/filing/0001161697-24-000225.json
- Plain text: https://secwatch.observer/filing/0001161697-24-000225.txt

## Key facts
- Earnings Releases
  KORU Medical Systems, Inc. reported full year 2024 results: revenue $31.2 million to $32.2 million. Guidance reaffirmed.
  - Period: full year 2024
  - Revenue: $31.2 million to $32.2 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Reaffirmed full year 2024 revenue guidance of $31.2 million to $32.2 million, representing growth of 10% to 13% over the prior year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/704440/000116169724000225/0001161697-24-000225-index.htm
- Earnings Releases
  KORU Medical Systems, Inc. reported first quarter ended March 31, 2024 results: revenue 8.2 million, net income net loss of $1.9 million, EPS $(0.04) per diluted share.
  - Period: first quarter ended March 31, 2024
  - Revenue: 8.2 million
  - Net income: net loss of $1.9 million
  - EPS: $(0.04) per diluted share
  - Result: reported results
  source text: large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights ● First quarter 2024 net revenues of $8.2 million, an 11% increase over the prior year and record high quarterly revenues ● Core business (U.S. and International) growth of 14% over the prior year, driven by overall SCIg market
  evidence_url: https://www.sec.gov/Archives/edgar/data/704440/000116169724000225/0001161697-24-000225-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.